Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Hohloch

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Infection and Immunity|September 1, 1994
Iron release from transferrin by pyoverdin and elastase from Pseudomonas aeruginosaC Wolz, K Hohloch, A Ocaktan, et al.
Gastroenterology|April 30, 1999
Rapid mucosal CD4(+) T-cell depletion and enteropathy in simian immunodeficiency virus-infected rhesus macaquesS Kewenig, T Schneider, K Hohloch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2013
Transformation and additional malignancies are leading risk factors for an adverse course of disease in marginal zone lymphomaA H Meyer, A Stroux, K Lerch, et al.
Nuklearmedizin. Nuclear Medicine|November 9, 2010
Retrospective web-based multicenter evaluation of ¹⁸F-FDG-PET and CT derived predictive factors. Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan in follicular non Hodgkin's lymphomaA Grgic, U Nestle, K Scheidhauer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 2004
Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study GroupC Kollmannsberger, J Beyer, R Liersch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 24, 2008
Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: I. A randomized dose escalation and feasibility study with bi- and tri-weekly regimensL Trümper, C Zwick, M Ziepert, et al.
Leukemia|September 27, 2008
The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG)C Buske, E Hoster, M Dreyling, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Infection and Immunity|September 1, 1994
Iron release from transferrin by pyoverdin and elastase from Pseudomonas aeruginosaC Wolz, K Hohloch, A Ocaktan, et al.
Gastroenterology|April 30, 1999
Rapid mucosal CD4(+) T-cell depletion and enteropathy in simian immunodeficiency virus-infected rhesus macaquesS Kewenig, T Schneider, K Hohloch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2013
Transformation and additional malignancies are leading risk factors for an adverse course of disease in marginal zone lymphomaA H Meyer, A Stroux, K Lerch, et al.
Nuklearmedizin. Nuclear Medicine|November 9, 2010
Retrospective web-based multicenter evaluation of ¹⁸F-FDG-PET and CT derived predictive factors. Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan in follicular non Hodgkin's lymphomaA Grgic, U Nestle, K Scheidhauer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 2004
Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study GroupC Kollmannsberger, J Beyer, R Liersch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 24, 2008
Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: I. A randomized dose escalation and feasibility study with bi- and tri-weekly regimensL Trümper, C Zwick, M Ziepert, et al.
Leukemia|September 27, 2008
The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG)C Buske, E Hoster, M Dreyling, et al.
Pageof 2